Your browser doesn't support javascript.
loading
FCRL1 immunoregulation in B cell development and malignancy.
Mamidi, Murali K; Huang, Jifeng; Honjo, Kazuhito; Li, Ran; Tabengwa, Edlue M; Neeli, Indira; Randall, Nar'asha L; Ponnuchetty, Manasa V; Radic, Marko; Leu, Chuen-Miin; Davis, Randall S.
Afiliación
  • Mamidi MK; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
  • Huang J; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
  • Honjo K; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
  • Li R; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
  • Tabengwa EM; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
  • Neeli I; Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN, United States.
  • Randall NL; Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN, United States.
  • Ponnuchetty MV; Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN, United States.
  • Radic M; Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN, United States.
  • Leu CM; Institute of Microbiology and Immunology, National Yang Ming ChiaoTung University, Taipei, Taiwan.
  • Davis RS; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
Front Immunol ; 14: 1251127, 2023.
Article en En | MEDLINE | ID: mdl-37822931
Immunotherapeutic targeting of surface regulatory proteins and pharmacologic inhibition of critical signaling pathways has dramatically shifted our approach to the care of individuals with B cell malignancies. This evolution in therapy reflects the central role of the B cell receptor (BCR) signaling complex and its co-receptors in the pathogenesis of B lineage leukemias and lymphomas. Members of the Fc receptor-like gene family (FCRL1-6) encode cell surface receptors with complex tyrosine-based regulation that are preferentially expressed by B cells. Among them, FCRL1 expression peaks on naïve and memory B cells and is unique in terms of its intracellular co-activation potential. Recent studies in human and mouse models indicate that FCRL1 contributes to the formation of the BCR signalosome, modulates B cell signaling, and promotes humoral responses. Progress in understanding its regulatory properties, along with evidence for its over-expression by mature B cell leukemias and lymphomas, collectively imply important yet unmet opportunities for FCRL1 in B cell development and transformation. Here we review recent advances in FCRL1 biology and highlight its emerging significance as a promising biomarker and therapeutic target in B cell lymphoproliferative disorders.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma / Neoplasias Límite: Animals / Humans Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma / Neoplasias Límite: Animals / Humans Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza